STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update
STRATA Skin Sciences (NASDAQ: SSKN) reported Q4 2024 financial results with revenue of $9.6 million, up 10% year-over-year. The company's global XTRAC® recurring revenue reached $5.5 million, while equipment revenue increased 23% to $3.8 million.
Full-year 2024 revenue was $33.6 million, slightly up from $33.4 million in 2023. Q4 gross margin improved to 60.1%, up 480 basis points from the previous year. The company reduced its domestic XTRAC® installed base to 864 devices while increasing average revenue per device to $5,906 (+6% YOY).
Notable developments include renewed 3-year agreements with distributors in China and Japan, XTRAC Momentum™ 1.0 device approval in Japan, and a $2.1 million registered direct offering. The company reported a net loss of $4.5 million for Q4 2024 and ended the year with $8.6 million in cash and equivalents.
STRATA Skin Sciences (NASDAQ: SSKN) ha riportato i risultati finanziari del Q4 2024 con un fatturato di 9,6 milioni di dollari, in aumento del 10% rispetto all'anno precedente. Il fatturato ricorrente globale di XTRAC® ha raggiunto i 5,5 milioni di dollari, mentre il fatturato delle attrezzature è aumentato del 23% a 3,8 milioni di dollari.
Il fatturato totale per l'anno 2024 è stato di 33,6 milioni di dollari, leggermente superiore ai 33,4 milioni di dollari del 2023. Il margine lordo del Q4 è migliorato al 60,1%, con un incremento di 480 punti base rispetto all'anno precedente. L'azienda ha ridotto la propria base installata di XTRAC® domestica a 864 dispositivi, aumentando al contempo il fatturato medio per dispositivo a 5.906 dollari (+6% rispetto all'anno precedente).
Sviluppi notevoli includono il rinnovo di accordi triennali con distributori in Cina e Giappone, l'approvazione del dispositivo XTRAC Momentum™ 1.0 in Giappone e un'offerta diretta registrata di 2,1 milioni di dollari. L'azienda ha riportato una perdita netta di 4,5 milioni di dollari per il Q4 2024 e ha chiuso l'anno con 8,6 milioni di dollari in contante e equivalenti.
STRATA Skin Sciences (NASDAQ: SSKN) reportó resultados financieros del Q4 2024 con ingresos de 9,6 millones de dólares, un aumento del 10% en comparación con el año anterior. Los ingresos recurrentes globales de XTRAC® alcanzaron los 5,5 millones de dólares, mientras que los ingresos por equipos aumentaron un 23% a 3,8 millones de dólares.
Los ingresos totales del año 2024 fueron de 33,6 millones de dólares, ligeramente superiores a los 33,4 millones de dólares de 2023. El margen bruto del Q4 mejoró al 60,1%, un aumento de 480 puntos básicos en comparación con el año anterior. La compañía redujo su base instalada de XTRAC® en el país a 864 dispositivos, mientras aumentaba los ingresos promedio por dispositivo a 5.906 dólares (+6% interanual).
Desarrollos notables incluyen la renovación de acuerdos de 3 años con distribuidores en China y Japón, la aprobación del dispositivo XTRAC Momentum™ 1.0 en Japón, y una oferta directa registrada de 2,1 millones de dólares. La empresa reportó una pérdida neta de 4,5 millones de dólares para el Q4 2024 y terminó el año con 8,6 millones de dólares en efectivo y equivalentes.
STRATA Skin Sciences (NASDAQ: SSKN)는 2024년 4분기 재무 결과를 보고하며 수익이 960만 달러로 전년 대비 10% 증가했다고 밝혔습니다. 회사의 글로벌 XTRAC® 반복 수익은 550만 달러에 달했으며, 장비 수익은 23% 증가하여 380만 달러에 이르렀습니다.
2024년 전체 수익은 3360만 달러로, 2023년의 3340만 달러에서 소폭 증가했습니다. 4분기 총 이익률은 60.1%로 개선되어 전년 대비 480 베이시스 포인트 상승했습니다. 회사는 국내 XTRAC® 설치 기기를 864대로 줄였고, 기기당 평균 수익을 5,906달러로 증가시켰습니다 (+6% 전년 대비).
주요 발전 사항으로는 중국과 일본의 유통업체와의 3년 계약 갱신, 일본에서의 XTRAC Momentum™ 1.0 장치 승인, 그리고 210만 달러의 등록 직접 제공이 포함됩니다. 회사는 2024년 4분기에 450만 달러의 순손실을 보고했으며, 연말에는 860만 달러의 현금 및 현금성 자산을 보유하고 있었습니다.
STRATA Skin Sciences (NASDAQ: SSKN) a annoncé ses résultats financiers pour le Q4 2024 avec un chiffre d'affaires de 9,6 millions de dollars, en hausse de 10% par rapport à l'année précédente. Les revenus récurrents mondiaux de XTRAC® ont atteint 5,5 millions de dollars, tandis que les revenus des équipements ont augmenté de 23% pour atteindre 3,8 millions de dollars.
Le chiffre d'affaires total pour l'année 2024 s'est élevé à 33,6 millions de dollars, légèrement supérieur aux 33,4 millions de dollars de 2023. La marge brute du Q4 s'est améliorée à 60,1%, en hausse de 480 points de base par rapport à l'année précédente. L'entreprise a réduit sa base installée de XTRAC® domestique à 864 appareils tout en augmentant le revenu moyen par appareil à 5 906 dollars (+6% en glissement annuel).
Les développements notables incluent le renouvellement d'accords de 3 ans avec des distributeurs en Chine et au Japon, l'approbation de l'appareil XTRAC Momentum™ 1.0 au Japon et une offre directe enregistrée de 2,1 millions de dollars. L'entreprise a enregistré une perte nette de 4,5 millions de dollars pour le Q4 2024 et a terminé l'année avec 8,6 millions de dollars en liquidités et équivalents.
STRATA Skin Sciences (NASDAQ: SSKN) berichtete über die finanziellen Ergebnisse des Q4 2024 mit einem Umsatz von 9,6 Millionen Dollar, was einem Anstieg von 10% im Vergleich zum Vorjahr entspricht. Der globale wiederkehrende Umsatz von XTRAC® erreichte 5,5 Millionen Dollar, während der Umsatz mit Geräten um 23% auf 3,8 Millionen Dollar anstieg.
Der Gesamtumsatz für das Jahr 2024 betrug 33,6 Millionen Dollar, leicht höher als die 33,4 Millionen Dollar im Jahr 2023. Die Bruttomarge im Q4 verbesserte sich auf 60,1%, was einem Anstieg von 480 Basispunkten im Vergleich zum Vorjahr entspricht. Das Unternehmen reduzierte seine inländische installierte Basis von XTRAC® auf 864 Geräte und erhöhte gleichzeitig den durchschnittlichen Umsatz pro Gerät auf 5.906 Dollar (+6% im Jahresvergleich).
Bemerkenswerte Entwicklungen umfassen die Erneuerung von 3-Jahres-Verträgen mit Distributoren in China und Japan, die Genehmigung des XTRAC Momentum™ 1.0 Geräts in Japan und ein registriertes Direktangebot von 2,1 Millionen Dollar. Das Unternehmen berichtete über einen Nettoverlust von 4,5 Millionen Dollar für das Q4 2024 und schloss das Jahr mit 8,6 Millionen Dollar in Bargeld und Äquivalenten ab.
- Q4 revenue increased 10% year-over-year to $9.6 million
- Gross margin improved 480 basis points to 60.1% in Q4
- Equipment revenue grew 23% to $3.8 million in Q4
- International sales increased 41% year-over-year in Q4
- Average revenue per XTRAC device improved 6% to $5,906
- Operating expenses reduced by 8.5% year-over-year
- 67% reduction in capex spend for full-year 2025
- Net loss increased to $4.5 million in Q4 2024 from $3.8 million in Q4 2023
- Domestic XTRAC installed base decreased to 864 from 923 systems
- Full-year recurring revenue segment declined 2%
- $3.9 million impairment expense recorded for 2024
- One-time accrued expense of $1.8 million in Q3 2024
Insights
STRATA's Q4 results demonstrate meaningful operational progress in their turnaround strategy despite mixed financial outcomes. Revenue reached
Gross margin improved significantly to
However, STRATA still faces challenges. The net loss widened to
The
HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update.
Fourth Quarter and Full-Year 2024 Financial Highlights
- Revenue in the fourth quarter of 2024 was
$9.6 million , up10% from$8.7 million in the year-ago quarter- Global net recurring XTRAC® revenue in the fourth quarter was
$5.5 million vs.$5.4 million in the prior year period, with international growth of13% more than offsetting a slight decline in the domestic market - Average net revenue per domestic XTRAC® system increased to
$5,906 (+6% YOY) on 864 systems in the fourth quarter vs.$5,555 per system on 923 systems in the comparable prior year period - Total Recurring revenue increased
3.0% to$5.8 million in the fourth quarter, driven by international growth and contribution from TheraClear - Equipment revenue of
$3.8 million increased23% vs.$3.1 million in the fourth quarter of 2023, representing our highest level in two years
- Global net recurring XTRAC® revenue in the fourth quarter was
- Full year 2024, revenue of
$33.6 million increased slightly vs.$33.4 million in 2023- While revenue for the full year was up only slightly, results improved significantly over the course of the year with Y/Y growth in the fourth quarter of
10% - For the full year, growth of
5% in the Equipment segment more than offset a decline of2% in the Recurring segment
- While revenue for the full year was up only slightly, results improved significantly over the course of the year with Y/Y growth in the fourth quarter of
- Gross margin of
60.1% in the fourth quarter of 2024, improved 480 bps vs.55.3% in the fourth quarter of 2023 - Adjusting for a one-time accrued expense of
$1.8 million in the third quarter of 2024 and the impact of non-cash impairment in both years, operating expense of$22.7 million in 2024 declined8.5% vs.$24.8 million in 2023 - Implemented a turnaround, focusing on cost efficiency and improving revenue per device, and delivered meaningful improvements in both metrics
- Drove efficiencies in Sales & Marketing to more than offset the increase in Direct-to-Consumer (DTC) spend associated with the reimplementation of the Company’s strategic revenue model
- Implemented a strategy to remove and refurbish underutilized machines, driving a
67% year-over-year reduction in capex spend for full-year 2025, further conserving cash
2024 Corporate Highlights
- Renewed 3-year agreements with exclusive distributors in China and Japan – each agreement carries minimum unit placements and/or purchases of the XTRAC® and VTRAC® devices
- Amended credit agreement with MidCap Financial Trust to ensure alignment with the Company’s current and future business projections
- On July 23, 2024, closed a registered direct offering that raised
$2.1 million in gross proceeds ($1.9 million in net proceeds) through the sale of 665,136 shares of common stock at an average purchase price of$3.16 per share, with participation from insiders and existing institutional shareholders - Received approval for the XTRAC Momentum™ 1.0 device in Japan and drove significant growth in international recurring revenue
- Upgraded clinical team and implemented a consulting model focused on best practices within customer clinics. Early results show meaningful improvement in procedures per device and, in some cases, demand for additional placements
- Filed a complaint against LaserOptek, and others, citing unfair competition under federal and state laws regarding the marketing and sales of competitive laser devices. On November 8, 2024 pursuant to a joint stipulation a court order was entered in the US District Court for the Eastern District of Pennsylvania enjoining LaserOptek, and all those acting at their direction from engaging in any sales, marketing or promotion of Pallas lasers that states or implies, that treatments with Pallas lasers are reimbursable using CPT Codes 96920-96922, and also barred LaserOptek and others from engaging in any deceptive advertising that includes any false or misleading statements regarding the Pallas lasers or STRATA’s lasers. On February 28, 2025, Strata filed a motion for civil contempt against LaserOptek for violating that court order.
“2024 was a year of execution for STRATA. Our fourth quarter results highlight the success we are having in implementing our strategy to shift our existing installed base from underperforming centers to more productive ones while utilizing our DTC and service model to help our customers succeed,” commented STRATA’s President and CEO Dr. Dolev Rafaeli. “We have reduced XTRAC® devices in our domestic installed base to 864, from 923 at the prior year end, resulting in average revenue per device increasing to
“With regard to our international markets, we have seen significant traction, with particular strength in the Equipment segment. During the fourth quarter, international sales increased to
Fourth Quarter 2024 Financial Results
Revenue for the fourth quarter of 2024 was
Gross profit for the fourth quarter of 2024 was
Selling and marketing costs for the fourth quarter of 2024 were
Net loss for the fourth quarter of 2024 was
Cash, cash equivalents, and restricted cash at December 31, 2024 were
Full Year 2024 Financial Results
Revenue for the full year 2024 was
Gross profit for the full year 2024 was
Selling and marketing costs for the full year 2024 were
Impairment expense for the full year 2024 was
Other expenses for the full year 2024 were
Net loss for the full year 2024 was
Fourth Quarter and Full Year 2024 Earnings Conference Call
STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
To listen to the conference call, interested parties within the U.S. should dial 1-844-481-2523 (domestic) or 1-412-317-0552 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.
The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences 4Q24 Earnings Webcast.
A telephonic replay of the call will be available until April 3, 2025 by dialing 1-877-344-7529 (or 1-412-317-0088 for international callers) and using replay access code 8210574. To access the replay using an international dial-in number, please see here.
A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until September 24, 2025.
Non-GAAP Financial Measures
STRATA has determined to supplement its consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), presented elsewhere within this report, with certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP gross profit, which excludes the non-cash expense of amortization of acquired intangible assets classified as cost of revenues, and non-GAAP adjusted EBITDA, “Earnings Before Interest, Taxes, Depreciation, and Amortization.”
These non-GAAP disclosures have limitations as an analytical tool, should not be viewed as a substitute for Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP, should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies. STRATA considers these non-GAAP measures in addition to its results prepared under current accounting standards, but they are not a substitute for, nor superior to, U.S. GAAP measures. These non-GAAP measures are provided to enhance readers’ overall understanding of STRATA’s current financial performance and to provide further information for comparative purposes. This supplemental presentation should not be construed as an inference that the Company's future results will be unaffected by similar adjustments to Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP. Specifically, STRATA believes the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of the Company’s core operating results and business outlook. In addition, STRATA believes non-GAAP measures enhance the comparability of results against prior periods.
Reconciliation to the most directly comparable U.S. GAAP measure of all non-GAAP measures included in this press release is as follows:
| Year Ended December 31, | |||||||
| (in thousands) | 2024 | 2023 | |||||
| Net loss | $ | (10,086 | ) | $ | (10,830 | ) | |
| Adjustments: | |||||||
| Depreciation and amortization | 4,968 | 5,553 | |||||
| Amortization of operating lease right-of-use asset | 339 | 349 | |||||
| Loss on disposal of property and equipment | 49 | 72 | |||||
| Benefit from income taxes | (170 | ) | (92 | ) | |||
| Interest income | (242 | ) | (231 | ) | |||
| Interest expense | 2,107 | 1,640 | |||||
| Non-GAAP EBITDA | (3,035 | ) | (3,539 | ) | |||
| Impairment of goodwill | 3,861 | 2,284 | |||||
| Stock-based compensation | 427 | 1,303 | |||||
| Loss on debt extinguishment | — | 909 | |||||
| Employee retention credit | (864 | ) | — | ||||
| Non-GAAP adjusted EBITDA | $ | 389 | $ | 957 | |||
| One-time accrual for NY State Sales Tax | 1,781 | — | |||||
| Non-GAAP adjusted EBITDA normalized for one-time events | 2,170 | 957 | |||||
XTRAC Gross Domestic Recurring Billings
XTRAC gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP adjustments, which are deferred revenue from prior quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This excludes international recurring revenues.
The following is a reconciliation of non-GAAP XTRAC gross domestic billings to domestic recorded revenue for the third quarter and first nine months of 2024 and 2023 (in thousands), respectively:
| Three Months EndedDecember31, | YTD | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Gross domestic recurring billings | |||||||||||||||
| Co-Pay adjustments | (84 | ) | (87 | ) | (331 | ) | (343 | ) | |||||||
| Other discounts | (6 | ) | (22 | ) | (81 | ) | (110 | ) | |||||||
| Deferred revenue from prior quarters | 1,867 | 1,913 | 7,204 | 8,114 | |||||||||||
| Deferral of revenue to future quarters | (1,545 | ) | (1,624 | ) | (7,126 | ) | (7,567 | ) | |||||||
| GAAP Recorded domestic revenue | |||||||||||||||
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
| STRATA Skin Sciences, Inc. and Subsidiary Condensed Consolidated Balance Sheets (in thousands, except share and per share data) | |||||||
| December 31, | |||||||
| 2024 | 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 7,261 | $ | 6,784 | |||
| Restricted cash | 1,334 | 1,334 | |||||
| Accounts receivable, net of allowance for credit losses of | 5,253 | 4,440 | |||||
| Inventories | 2,246 | 2,673 | |||||
| Prepaid expenses and other current assets | 501 | 312 | |||||
| Total current assets | 16,595 | 15,543 | |||||
| Property and equipment, net | 10,061 | 11,778 | |||||
| Operating lease right-of-use assets | 1,264 | 626 | |||||
| Intangible assets, net | 5,348 | 7,319 | |||||
| Goodwill | 2,658 | 6,519 | |||||
| Other assets | 231 | 231 | |||||
| Total assets | $ | 36,157 | $ | 42,016 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 2,433 | $ | 3,343 | |||
| Accrued expenses and other current liabilities | 8,593 | 6,306 | |||||
| Deferred revenues | 2,241 | 2,120 | |||||
| Current portion of operating lease liabilities | 328 | 352 | |||||
| Current portion of contingent consideration | 1,030 | 53 | |||||
| Total current liabilities | 14,625 | 12,174 | |||||
| Long-term debt, net | 15,192 | 15,044 | |||||
| Deferred revenues and other liabilities | 353 | 552 | |||||
| Deferred tax liability | — | 186 | |||||
| Operating lease liabilities, net of current portion | 919 | 237 | |||||
| Contingent consideration, net of current portion | 96 | 1,135 | |||||
| Total liabilities | 31,185 | 29,328 | |||||
| Commitments and contingencies (Note 10) | |||||||
| Stockholders’ equity: | |||||||
| Series C convertible preferred stock, | — | — | |||||
| Common stock, | 4 | 4 | |||||
| Additional paid-in capital | 253,112 | 250,742 | |||||
| Accumulated deficit | (248,553 | ) | (238,058 | ) | |||
| Total stockholders’ equity | 4,972 | 12,688 | |||||
| Total liabilities and stockholders’ equity | $ | 36,157 | $ | 42,016 | |||
| STRATA Skin Sciences, Inc. and Subsidiary Condensed Consolidated Statements of Operations (in thousands, except share and per share data) | |||||||
| Year Ended December 31, | |||||||
| 2024 | 2023 | ||||||
| Revenues, net | $ | 33,562 | $ | 33,358 | |||
| Cost of revenues | 14,481 | 14,897 | |||||
| Gross profit | 19,081 | 18,461 | |||||
| Operating expenses: | |||||||
| Engineering and product development | 883 | 1,317 | |||||
| Selling and marketing | 12,289 | 12,956 | |||||
| General and administrative | 11,303 | 10,508 | |||||
| Impairment of goodwill | 3,861 | 2,284 | |||||
| 28,336 | 27,065 | ||||||
| Loss from operations | (9,255 | ) | (8,604 | ) | |||
| Other (expense) income: | |||||||
| Interest expense | (2,107 | ) | (1,640 | ) | |||
| Interest income | 242 | 231 | |||||
| Loss on debt extinguishment | — | (909 | ) | ||||
| Other income | 864 | — | |||||
| (1,001 | ) | (2,318 | ) | ||||
| Loss before benefit from income taxes | (10,265 | ) | (10,922 | ) | |||
| Benefit from income taxes | 170 | 92 | |||||
| Net loss | $ | (10,086 | ) | $ | (10,830 | ) | |
| Net loss per share of common stock, basic and diluted | $ | (2.65 | ) | $ | (3.10 | ) | |
| Weighted average shares of common stock outstanding, basic and diluted | 3,807,186 | 3,491,964 | |||||
| STRATA Skin Sciences, Inc. and Subsidiary Condensed Consolidated Statements of Cash Flows (in thousands) | |||||||
| Year Ended December 31, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (10,086 | ) | $ | (10,830 | ) | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||||||
| Depreciation and amortization | 4,968 | 5,553 | |||||
| Impairment of goodwill | 4,861 | 2,284 | |||||
| Amortization of operating lease right-of-use assets | 339 | 349 | |||||
| Amortization of deferred financing costs and debt discount | 148 | 140 | |||||
| Change in allowance for credit losses | (182 | ) | (110 | ) | |||
| Stock-based compensation expense | 427 | 1,303 | |||||
| Loss on debt extinguishment | — | 909 | |||||
| Loss on disposal of property and equipment | 49 | 72 | |||||
| Inventory write-off | 162 | — | |||||
| Deferred income taxes | (186 | ) | (120 | ) | |||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (631 | ) | 141 | ||||
| Inventories | 572 | 689 | |||||
| Prepaid expenses and other assets | (189 | ) | 246 | ||||
| Accounts payable | (954 | ) | (100 | ) | |||
| Accrued expenses and other liabilities | 2,266 | (197 | ) | ||||
| Deferred revenues | (57 | ) | (472 | ) | |||
| Operating lease liabilities | (319 | ) | (376 | ) | |||
| Net cash provided by (used in) operating activities | 188 | (519 | ) | ||||
| Cash flows from investing activities: | |||||||
| Purchase of property and equipment | (1,636 | ) | (5,019 | ) | |||
| Net cash used in investing activities | (1,636 | ) | (5,019 | ) | |||
| Cash flows from financing activities: | |||||||
| Proceeds from long-term debt | — | 7,000 | |||||
| Payment of deferred financing costs | — | (97 | ) | ||||
| Payment of contingent consideration | (18 | ) | (42 | ) | |||
| Sale of common stock, net of offering costs | 1,943 | — | |||||
| Net cash provided by financing activities | 1,925 | 6,861 | |||||
| Net increase in cash, cash equivalents and restricted cash | 477 | 1,323 | |||||
| Cash, cash equivalents and restricted cash at beginning of year | 8,118 | 6,795 | |||||
| Cash, cash equivalents and restricted cash at end of year | $ | 8,595 | $ | 8,118 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Cash paid during the year for interest | $ | 1,973 | $ | 1,415 | |||
| Cash paid during the year for income taxes | $ | 23 | $ | 22 | |||
| Supplemental schedule of non-cash operating, investing and financing activities: | |||||||
| Modification of common stock warrants | $ | — | $ | 384 | |||
| Transfer of property and equipment to inventories | $ | 307 | $ | 267 | |||
| Change in intangible assets and fair value of contingent consideration | $ | — | $ | 7,374 | |||
| Accrued exit fee recorded as debt discount | $ | 150 | $ | 450 | |||
| Accrued payment of contingent consideration | $ | 44 | $ | 18 | |||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $ | 977 | $ | — | |||
FAQ
What was STRATA Skin Sciences (SSKN) Q4 2024 revenue growth?
How did SSKN's XTRAC revenue per device perform in Q4 2024?
What was STRATA's (SSKN) gross margin improvement in Q4 2024?
How much capital did SSKN raise in their July 2024 offering?
What was STRATA's (SSKN) international revenue performance in Q4 2024?
